Skip to content

The effect of rose hip alcoholic extract on the ventricular arrhythmia

Investigating the effect of rose hip alcoholic extract on the ventricular arrhythmia in heart failure patients with Implantable Cardioverter Defibrillator

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220516054874N17
Enrollment
72
Registered
2024-07-05
Start date
2024-07-05
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular arrhythmia. Paroxysmal tachycardia

Interventions

Intervention 1: Intervention group: Taking rose hip alcoholic extract 250 mg tablets four times a day for one month. Intervention 2: Control group: Taking placebo tablets, which look exactly like 250

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age older than 18 years old Heart failure diagnosis ICD implantation > 6 months before eligibility test Signed written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: New York Heart Association Class IV heart failure Renal dysfunction with eGFR < 20 Hepatic dysfunction Body mass index < 18.5 kg/m2 Pregnant or suspected pregnancy Patients with the following events within 3months before the eligibility test: alteration of antiarrhythmic drug, catheter ablation for ventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization, heart failure requiring hospitalization Other comorbidities including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer ICDs unable to record cardiac arrhythmias

Design outcomes

Primary

MeasureTime frame
Frequency of the ventricular arrhythmias (PVC, NSVT, VT, VF). Timepoint: The beginning of the study and one months later. Method of measurement: ICD (implantable cardioverter-defibrillator) record.

Secondary

MeasureTime frame
Hospitalization. Timepoint: The beginning of the study and one month later. Method of measurement: Checklist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Zahra Zandi

Mashhad University of Medical Sciences

zandiz@mums.ac.ir0095 5138012739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026